Octreotide — Discount Pricing
Octreotide is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Octreotide Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $132.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Octreotide
Octreotide is a prescription medication. Ask your doctor if Octreotide is right for you.
How to Check Octreotide Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Octreotide at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Hormones
What Octreotide is approved for (FDA label)
MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide ( 1 ).
Source: Read the full FDA label on DailyMed. Label effective date: July 24, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Octreotide (FDA label)
Delayed-release capsules: 20 mg. White hard gelatin capsules imprinted with "OT" on one half of the capsule and "20" on the other half. Each capsule contains 20 mg octreotide, provided as octreotide acetate. Delayed-release capsules: 20 mg.
Source: FDA prescribing information (DailyMed). Set ID: 58d80bc6-bdfb-4908-93e7-aace447c8d1a. SPL document ID: 84ca5e5f-886b-4216-b748-f7dad1201db0. Label effective date: July 24, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Octreotide (FDA label)
The following important adverse reactions are described below and elsewhere in the labeling: Cholelithiasis and Complications of Cholelithiasis [see Warnings and Precautions (5.1) ] Hyperglycemia and Hypoglycemia [see Warnings and Precautions (5.2) ] Thyroid Function Abnormalities [see Warnings and Precautions (5.3) ] Cardiac Function Abnormalities [see Warnings and Precautions (5.4) ] Steatorrhea and Malabsorption of Dieatary Fats [see Warnings and Precautions (5.5) ] Changes in Vitamin B 12 Levels [ see Warnings and Precautions (5.6) ] Most common adverse reactions (incidence >10 %) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, osteoarthritis ( 6.1 ).
Source: FDA prescribing information (DailyMed). Set ID: 58d80bc6-bdfb-4908-93e7-aace447c8d1a. SPL document ID: 84ca5e5f-886b-4216-b748-f7dad1201db0. Label effective date: July 24, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Octreotide (FDA label)
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide [see Adverse Reactions (6.3) ]. Hypersensitivity to octreotide or any of the components of MYCAPSSA.
Source: FDA prescribing information (DailyMed). Set ID: 58d80bc6-bdfb-4908-93e7-aace447c8d1a. SPL document ID: 84ca5e5f-886b-4216-b748-f7dad1201db0. Label effective date: July 24, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Octreotide (FDA label)
Cholelithiasis and Complications of Cholelithiasis: Monitor periodically. Discontinue if complications of cholelithiasis are suspected ( 5.1 ). Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ). Thyroid Function Abnormalities: Hypothyroidism may occur. Assess thyroid function periodically ( 5.3 ). Cardiac Function: Bradycardia, arrhythmia, or conduction abnormalities may occur. Drugs that have bradycardia effects may need dosage adjustments ( 5.4 , 7.2 ). Steatorrhea and Malabsorption of Dietary Fats: New onset steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency ( 5.5 ) Change in vitamin B12 levels: Monitor vitamin B 12 levels during treatment ( 5.6 ). 5.1 Cholelithiasis and Complications of Cholelithiasis MYCAPSSA may inhibit gallbladder contractility and decrease bile secretion, which may lead to gallbladder abnormalities or sludge.
Source: FDA prescribing information (DailyMed). Set ID: 58d80bc6-bdfb-4908-93e7-aace447c8d1a. SPL document ID: 84ca5e5f-886b-4216-b748-f7dad1201db0. Label effective date: July 24, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.